Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Vandel

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Medical Hypotheses|December 1, 1996
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effectsP Vandel, B Bonin, S Vandel, et al.
L'Encephale|August 6, 1999
[Clinical tolerance of a new antidepressant -- milnacipran]W Regina, P Vandel, S Vandel, et al.
Therapie|April 27, 2001
Loxapine side-effects: 3 case reports of hyperleukocytosisE Haffen, P Vandel, S Vandel, et al.
L'Encephale|June 30, 2000
[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]K Reggiani, P Vandel, E Haffen, et al.
L'Encephale|April 17, 1999
[Grapefruit juice as a contraindication? An approach in psychiatry]P Vandel, W Regina, I Reix, et al.
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
L'Encephale|July 6, 2013
[Sexual dysfunction and depression: Validity of a French version of the ASEX scale]M Briki, E Haffen, J Monnin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|December 3, 2014
Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopramD Bennabi, M Nicolier, J Monnin, et al.
Therapie|September 1, 2000
Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?P Vandel, E Haffen, S Vandel, et al.
Human Psychopharmacology|December 1, 2004
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetineP Vandel, D Sechter, E Weiller, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Medical Hypotheses|December 1, 1996
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effectsP Vandel, B Bonin, S Vandel, et al.
L'Encephale|August 6, 1999
[Clinical tolerance of a new antidepressant -- milnacipran]W Regina, P Vandel, S Vandel, et al.
Therapie|April 27, 2001
Loxapine side-effects: 3 case reports of hyperleukocytosisE Haffen, P Vandel, S Vandel, et al.
L'Encephale|June 30, 2000
[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]K Reggiani, P Vandel, E Haffen, et al.
L'Encephale|April 17, 1999
[Grapefruit juice as a contraindication? An approach in psychiatry]P Vandel, W Regina, I Reix, et al.
Human Psychopharmacology|July 15, 2004
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patientsP Vandel, E Haffen, S Nezelof, et al.
L'Encephale|July 6, 2013
[Sexual dysfunction and depression: Validity of a French version of the ASEX scale]M Briki, E Haffen, J Monnin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|December 3, 2014
Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopramD Bennabi, M Nicolier, J Monnin, et al.
Therapie|September 1, 2000
Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?P Vandel, E Haffen, S Vandel, et al.
Human Psychopharmacology|December 1, 2004
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetineP Vandel, D Sechter, E Weiller, et al.
Pageof 5